Indications and problems of long-term coagulation inhibition with drugs;Indikationen und Probleme langfristiger medikamentoser Gerinnungshemmung

Internist

Volumn 38, Issue 7, 1997, Pages 672-679

  Ostermann, H ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Med Klinik C Kardiologie/Angiologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; PHENPROCOUMON; PHYTOMENADIONE;

HEART VALVE REGURGITATION; HEART VALVE REPLACEMENT; HUMAN; ORAL DRUG ADMINISTRATION; REVIEW; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS PREVENTION; AGED; BLOOD; BLOOD CLOTTING TEST; DOSE RESPONSE; FEMALE; LONG TERM CARE; MALE; MIDDLE AGED; RISK FACTOR;

AGED; ANTICOAGULANTS; BLOOD COAGULATION TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; RISK FACTORS; THROMBOEMBOLISM;

EID: 0030813874     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050079     Document Type: Review

References (63)

1. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators (1990) The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 323:1505-1511
2. Stroke Prevention in Atrial Fibrillation Study. Final results (1991) Circulation 84:527-539
3. EAFT (European Atrial Fibrillation Trial) Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342:1255-1262
4. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study (1994) Lancet 343:687-691
5. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data for five randomized controlled trials (1994) Arch Intern Med 154:1449-1457
6. ACC/AHA guidelines for the management of patients with acute myocardial infarction (1996) J Am Coll Cardiol 28:1328-1428
7. Adjusted dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial (1996) Lancet 348:633-638
8. Aboaf AP, Wolf PS (1996) Paroxysmal atrial fibrillation. Arch Intern Med 156:362-367
9. Almony GT, Lefkovits J, Topol E (1996) Antiplatelet and anticoagulant use after myocardial infarction. Clin Cardiol 19:357-365
10. Ansell JA, Patel N, Ostrovsky D, Nozzolillo E, Petterson AM, Fish L (1995) Long-term patient self-management of oral anticoagulation. Arch Intern Med 155:2185-2189
11. Atrial fibrillation investigators (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis from pooled data from five randomized controlled trials. Arch Intern Med 154:1449-1457
12. Atwood JE, Albers GW (1993) Anticoagulation and atrial fibrillation. Herz 18:27-38
13. Azar AJ, Cannegieter SC, Deckers JW, Briet E, van Bergen PFMM, Jonker JJC, Rosendaal FR (1996) Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 27:1349-1355
14. Bernardo A, Halhuber C, Horstkotte D (1992) Home prothrombin estimation. In: Butchart EG, Bodnar E (Hrsg) Thrombosis, embolism and bleeding. ICR Publishers, London, S 325-330
15. Butchart EG, Lewis PA, Bethel JA, Breckenridge IM (1991) Adjusting anticoagulation to prosthesis thrombogenicity and patient risk factors. Recommendations for the Medtronic Hall valve. Circulation 84 (Suppl):III61-69
16. Cairns JA, Lewis HDJ, Meade TW, Sutton GC, Theroux P (1995) Antithrombotic agents in coronary artery disease. Chest 108:380S-400S
17. Cannegieter SC, Rosendaal FR, Briet E (1994) Thromboembolic and bleeding complications in patients with mechanical heart valve prosthesis. Circulation 89:635-641
18. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briet E (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333:11-17
19. Cappelleri JC, Fiore LD, Brophy MT, Deykin D, Lau J (1995) Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart-valve replacement: A metaanalysis. Am Heart J 130:547-552
20. Clagett GR Krupski WC (1995) Antithrombotic therapy in peripheral arterial occlusive disease. Chest 108:431S-443S
21. Cleland JGF, Cowburn PJ, Falk RH (1996) Should all patients with atrial fibrillation receive warfarin? Eur Heart J 17:674-681
22. Comp PC, Elrod JP, Karzenski S (1990) Warfarin-induced skin necrosis. Semin Thromb Hemoast 16:293-298
23. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C (1991) Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 18:349-355
24. Dahlman T, Lindvall N, Hellgren M (1990) Osteopenia in pregnancy during long-term heparin treatment: a radiological study post partum. Br J Obstet Gynaecol 97:221-228
25. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, et al. (1992) Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 327:1406-1412
26. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH (1996) The risk and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 124:970-979
27. Gage BF, Cardinalli AB, Albers GW, Owens DK (1995) Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 274:1839-1845
28. Genewein U, Haeberli A, Straub PW, Beer JH. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 1996;92479-92485
29. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996; 335(24):1816-1828
30. Ginsberg JS, Hirsh J (1995) Use of antithrombotic agents during pregnancy. Chest 108 (Suppl):305S-311S
31. Ginsberg JS, Hirsh J, Rainbow AJ, Coates G (1989) Risks to the fetus of radiologic procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost 61:189-196
32. Ginsberg JS, Hirsh J,Turner DC, Levine MN, Burrows R (1989) Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 61:197-203
33. Gohlke-Bärwolf C, Acar J, Oakley C, Butchari E, Burckhardt D, Bodnar E, Hall R, Delahaye J-P, Horstkotte D, Kremer R, Krayenbühl HP, Krzeminska-Pakula M, Samama M (1995) Guidelines for prevention of thromboembolic events in valvular heart disease. Eur Heart J 16:1320-1330
34. Golzari H, Cebul RD, Bahler RC (1996) Atrial fibrillation: Restoration and maintenance of sinus rhythm and indications for anticoagulant therapy. Ann Intern Med 125:311-323
35. Göhlke-Bärwolf C, Acar J, Oakley C, Butchart E, Buckhardt D, Delahaye J-P, Horstkotte D, Bodnar E, Hall R, Kremer R, Krayenbühl HP, Krzeminska-Pakula M, Samama M (1995) Empfehlungen zur Thromboembolieprophylaxe bei Herzklappenerkrankungen. Z Kardiol 84:1018-1032
36. Grip L, Blombäck M, Schulman S (1991) Hypercoagulable state and thromboembolism following warfarin withdrawal in postmyocardial-infarction patients. Eur Heart J; 121225-121233
37. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J (1997) Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med; 126:133-136
38. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H (1995) Oral anticoagulants. Mechanism if action, clinical effectiveness, and optimal therapeutic range. Chest; 108:2315-2465
39. Hirsh J, Hoak J (1996) Management of deep vein thrombosis and pulmonary embolism. Circulation 93:2212-2245
40. Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, McLeoughlin D, Armstrong P (1979) Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 301:855-858
41. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P (1982) Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 307:1676-1681
42. Hylek EM, Skates SJ, Sheehan MA, Singer DE (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335:540-546
43. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt B, Hughes GRV (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993-997
44. Landefeld CS, Goldman L (1989) Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87:144-152
45. Laupacis A, Alberts G, Dalen JE, Dunn M, Feinberg W, Jacobson A (1995) Antithrombotic therapy in atrial fibrillation. Chest 108:352S-359S
46. Levine HJ, Pauker SG, Eckman MH (1995) Antithrombotic therapy in valvular heart disease. Chest 108:360S-370S
47. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg JS, Geerts W, LeClerc J, Neemeh J, Powers P, Piovella F (1995) Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 74:606-611
48. Makris M, Bardham G, Preston FE (1996) Warfarin induced skin necrosis associated with activated protein C resistance. Thromb Haemost 75:523-524
49. Morley JM, Marinchak R, Rials SJ, Kowey P (1996) Atrial fibrillation, anticoagulation, and stroke. Am J Cardiol 77:38A-44A
50. Orme ML, Lewis PJ, de Swiet M, Serlin MJ, Sibeon R, Baty JD, Breckenridge AM (1977) May mothers given warfarin breast-feed their infants? Br Med J 1:1564-1565
51. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective colloborative study (ISCOAT). Lancet 348:423-428
52. Palareti G, Legnani C, Guazzaloca G, Frascaro M, Grauso F, De Rosa F, Fortunato G, Coccheri S (1994) Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants - a prospective study. Thromb Haemost 72:222-226
53. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B (1989) Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1:175-179
54. Research Committee of the British Thoracic Society (1992) Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. The Lancet 340:873-876
55. Salazar E, Izaguirre R, Verdejo J, Mutchinik O (1996) Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. J Am Coll Cardiol 27:1698-1703
56. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund S-G, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E, and the duration of anticoagulation trial study group (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 336:393-398
57. Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Logogna E, Svensson E, Ljunberg B, Walter H, Viering S, Nordlander S, Leijd B, Jönsson K-A, Hjorth M, Linder O, Boberg J, and the duration of anticoagulation trial study group (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 33:1661-1665
58. Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A (1997) The risk of recurrent venous thromboembolism in patients with the Arg506→Gln Mutation in the gene for factor V (Factor V Leiden). N Engl J Med 336:399-403
59. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AGG (1995) Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 108:371S-379S
60. Stein PD, Grandison D, Hua TA, Slettehaugh PM, Henry JW, Turlapaty P, Kerwin R (1994) Therapeutic level of oral anticoagulation with warfarin in patients with mechanical prosthetic heart valves: review of literature and recommendations based on international normalized ratio. Postgrad Med J 70 (Suppl 1):S72-83
61. Tardy B, Tardy-Poncet B, Laporte-Simitsidis S, Mismetti P, Decousus H, Guyotat D, Bertrand JC (1997) Evolution of blood coagulation and fibrinolysis parameters after abrupt versus gradual withdrawal ofacenocoumarol in patients with venous thromboembolism: a double-blind randomized study. Br J Haematol 96:174-178
62. The stroke prevention in atrial fibrillation investigators (1996) Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 156:409-416
63. Toglia MR, Weg JG (1996) Venous thromboembolism during pregnancy. N Engl J Med 335:108-114